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Background. Mobilization of c-Kit+ hematopoietic cells (HCs) contributes to tumor vascularization. Whereas survival and
proliferation of HCs are regulated by binding of the stem cell factor to its receptor c-Kit, migration of HCs is directed by stromal
cell-derived factor (SDF)-1. Therefore, targeting migration of HCs provides a promising new strategy of anti-tumor therapy.
Methods.BALB/cmice(n = 16)werepretreatedwithananti-c-KitantibodyfollowedbyimplantationofCT26.WT-GFPcolorectal
cancer cells into dorsal skinfold chambers. Animals (n = 8) additionally received a neutralizing anti-SDF-1 antibody. Animals
(n = 8) treated with a control antibody served as controls. Investigations were performed using intravital ﬂuorescence microscopy,
immunohistochemistry, ﬂow cytometry and western blot analysis. Results. Blockade of c-Kit signiﬁcantly enhanced tumor cell
engraftment compared to controls due to stimulation of tumor cell proliferation and invasion without markedly aﬀecting tumor
vascularization. C-Kit blockade signiﬁcantly increased VEGF and CXCR4 expression within the growing tumors. Neutralization
of SDF-1 completely antagonized this anti-c-Kit-associated tumor growth by suppression of tumor neovascularization, inhibition
of tumor cell proliferation and reduction of muscular inﬁltration. Conclusion. Our study indicates that bone marrow suppression
via anti-c-Kit pretreatment enhances tumor cell engraftment of colorectal metastases due to interaction with the SDF-1/CXCR4
pathway which is involved in HC-mediated tumor angiogenesis.
1.Introduction
Angiogenesis is one of the crucial steps in tumor progression
and metastasis [1, 2]. Due to the lack of oxygen supply
and the accumulation of toxic products, avascular tumors
and tumor metastases cannot grow beyond a critical size
of ∼1-2mm and thus will stay clinically occult [1, 3, 4].
Therefore, only a small proportion of circulating cancer cells
ﬁnally forms macroscopic tumors [5]. Tumor vessels can
growbysproutingofpreexistinghostvessels,intussusception
or incorporation of bone marrow-derived endothelial pro-
genitor cells (EPCs) which are a subset of hematopoietic cells
(HCs). This mechanism is called vasculogenesis and mimics
embryonic angio-development [2].
Although EPCs incorporate into tumors in only small
numbers, targeting EPCs has been shown to be eﬀective
in reducing tumor angiogenesis and tumor growth in
experimental models [6]. One of the most important factors
mediating survival and proliferation of HCs is the stem
cell factor (SCF) which binds to the c-Kit receptor on the
surfaceofHCs.Okamotoetal.haveshownthatbonemarrow
suppression by anti-c-Kit treatment induces a delay in tumor
angiogenesis due to the inhibition of angiogenic sprouting
in colon tumors and that c-Kit blockade suppresses tumor
growth of subcutaneously implanted prostate carcinomas
(PC3) by inhibition of tumor angiogenesis regulated by HCs
[7].2 Journal of Oncology
Recruitment of HCs and EPCs to avascular areas is
orchestrated by diﬀerent angiogenic growth factors and
cytokines [8], predominantly by the CXC-chemokine stro-
mal cell-derived factor (SDF)-1 and its receptor CXCR4
[9, 10]. HCs and EPCs ﬂuctuate to peripheral organs in
antiphase with the expression of SDF-1 within the bone
marrow microenvironment [11] and migrate alongside a
chemotactic gradient towards higher concentrations of SDF-
1, for example, sites of injury and tumor tissue [12–
14]. Furthermore, it has been demonstrated that SDF-1-
mediated recruitment of c-Kit-positive cells to the periphery
is dependent on cofactors, including tumor necrosis factor-α
and the endothelial nitric oxide synthase (eNOS) [12].
However, the impact of circulating HCs and EPCs on
vasculogenesis and sprouting angiogenesis in tumor angio-
development is still controversially discussed in the literature
[15–17], and the role of the SDF-1/CXCR4 pathway is
not yet fully understood. Therefore, in the presented study
we analyzed the inﬂuence of bone marrow suppression by
anti-c-Kit treatment combined with SDF-1 neutralization
on tumor cell engraftment and neovascularization using a
murine model of colorectal tumor metastasis.
2.MaterialsandMethods
2.1. Tumor Cell Line and Culture Conditions. The CT26
cell line is an N-nitroso-N-methyl-urethane-induced undif-
ferentiated adenocarcinoma of the colon, syngeneic with
the BALB/c mouse. For our studies [18], the CT26.WT
cells (ATCC CRL-2638, LGC Promochem GmbH, Wesel,
Germany) were transfected with the enhanced GFP expres-
sion vector pEGFP-N1 (Clontech) with the use of CLON-
fectin (Clontech, Palo Alto, CA, USA) according to the
manufacturer’s instructions. For the individual experiments,
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layers in RPMI-1640 medium with 2mM L-glutamine
(Sigma Aldrich Chemie GmbH, Taufkirchen, Germany)
supplemented with 10% fetal calf serum (FCS Gold, PAA
Laboratories GmbH, C¨ olbe, Germany), 100U/mL penicillin,
and 100μg/mL streptomycin (PAA Laboratories GmbH).
The cells were incubated at 37◦C in a humidiﬁed atmosphere
containing 5% CO2, and only cells of the ﬁrst three
serial passages after cryostorage were used. At the day of
implantation, tumor cells were harvested from subconﬂuent
cultures (70 to 85%) by trypsinization (0.05% Trypsin and
0.02% EDTA, PAA Laboratories GmbH) and washed twice
in phosphate-buﬀered saline solution (PBS).
2.2. Animals. Experiments were performed after approval by
the local governmental ethic committee and conformed to
the United Kingdom Coordinating Committee on Cancer
Research (UKCCCR) Guidelines for the Welfare of Animals
in Experimental Neoplasia (as described in 1998 in Br J Can-
cer 77: 1–10) and the Guide for Care and Use of Laboratory
Animals(InstituteofLaboratoryAnimalResources,National
Research Council; NIH Guide, Vol. 25, No. 28, 1996). Female
BALB/c mice (Charles River Laboratories GmbH; Sulzfeld,
Germany) with a body weight (BW) of 18–20g were used.
Theanimalswerehousedinsinglecagesatroomtemperature
of 22–24◦C and at a relative humidity of 60–65% with a 12-
hour light/dark cycle environment. The mice were allowed
free access to drinking water and standard laboratory chow
(Altromin; Lage, Germany).
2.3. Experimental Model—Dorsal Skinfold Chamber. To
allow repetitive analyses of the microcirculation of the grow-
ing tumors, the dorsal skinfold chamber model was used
for intravital microscopy as described previously in detail
[19]. For operative procedures, animals were anesthetized by
intraperitoneal injection of 90mg/kg BW ketamine (Ketavet,
Parke Davis; Freiburg, Germany) and 20mg/kg BW xylazine
(Rompun, Bayer; Leverkusen, Germany). The chamber, con-
sisting of two symmetrical titanium frames, was positioned
to sandwich the extended double layer of the dorsal skin.
One layer of skin and subcutis was completely removed in
a circular area of 15mm diameter. The remaining layers,
consistingoftheepidermis,subcutaneoustissue,andstriated
skin muscle, were covered with a glass coverslip incorporated
into one of the titanium frames. The animals tolerated the
chambers well and showed no signs of discomfort or changes
in sleeping and feeding habits. After a 48-hour recovery
period, the animals were reanesthetized. For tumor cell
implantation, the coverslip of the chamber was temporarily
removed and 1 × 105 CT26.WT-GFP cells were implanted
onto the surface of the striated muscle tissue within the
chamber. Immediately after cell implantation, the chamber
tissue was covered again with the coverslip [20–22].
2.4. Experimental Protocol. Animals were assigned to three
diﬀerent groups: the ﬁrst group (cKit-Ab; n = 8) received
a pretreatment with a monoclonal anti-c-Kit receptor anti-
body (ACK45, BD Biosciences, Heidelberg, Germany) by
daily intraperitoneal injections starting 4 days before tumor
cell implantation. The ACK45-antibody was given four times
at a dose of 1mg/kg BW daily as described by Okamoto
et al. [7]. Animals of the second group (cKit/SDF1-Ab;
n = 8) were also pretreated with ACK45 as described
above. Additionally, these animals received 1mg/kg BW of a
monoclonalmouseanti-mouseSDF-1antibody(MAB310,R
and D Systems, Wiesbaden, Germany). MAB310 application
was performed intraperitoneally, starting at the day of
tumor cell implantation (d0) and repeated every second day
thereafter until day 12. The third group (control; n = 8)
served as control and received pre- and posttreatment the
same amount of the corresponding isotype-matched IgG
control antibodies (A95-1, BD Biosciences, and MAB002
R&D Systems). All animals underwent repetitive intravital
microscopic analyses directly (d0) as well as 5, 8, 11, and
14 days after tumor cell implantation. At the end of the
experiment (day 14), the chamber with the tumor tissue was
harvested for histology and immunohistochemistry.
2.5. Intravital Fluorescence Microscopy. Intravital ﬂuores-
cence microscopy was performed in epi-illumination tech-
nique using a modiﬁed Zeiss Axio-Tech microscope (Zeiss,
Oberkochen, Germany) with a 100-W HBO mercury lamp.Journal of Oncology 3
Microscopic images were monitored by a charge-coupled
device video camera (FK 6990, COHU, Prospective Mea-
surements Inc., San Diego, CA, USA) and were transferred
to a video system (VO-5800 PS, Sony, M¨ unchen, Germany)
for subsequent oﬀ-line analysis. Tumor size, growth kinet-
ics, migration of tumor cell, and neovascularization were
analyzed using blue light epi-illumination (450 to 490nm
excitation wavelength and >520nm emission wavelengths)
[20–22].
2.6. Microcirculation Analysis. Microcirculatory parameters
were assessed oﬀ line by frame-to-frame analysis of the
videotaped images using a computer-assisted image analysis
system (CapImage, Zeintl Software, Heidelberg, Germany).
The ﬂuorescent labeling of the tumor cells allowed precise
delineation of the tumor from the surrounding host tissue.
It also enabled for distinct identiﬁcation of individual tumor
cells to study tumor cell migration. At each observation time
point, the surface of the ﬂuorescently labeled tumor mass
within the chamber was scanned for determination of the
tumor size (given as tumor area in mm2). Eight regions of
interest (ROIs) were randomly chosen next to the tumor
margin. The number of migrating cells was counted, and the
distance to the tumor margin was measured (given in μm).
Microcirculation was quantiﬁed as described before in
detail [22]. First, eight representative ROIs within the tumor
margin were chosen and analyzed for microcirculation
parameters. In these ROIs, the onset of angiogenesis, that is,
the existence of angiogenic buds, sprouts, and newly formed
blood vessels, was documented and scored 0 to 8, with 0
indicating existence of newly formed tumor microvessels in
none of the ROIs and 8 indicating their existence in all of
the ROIs. Functional capillary density (given in cm/cm2)
of the tumor microvessels was measured to quantify the
angiogenic activity. This parameter was deﬁned as the length
of red blood cell perfused microvessels per observation
area and was analyzed within the eight ROIs of the tumor
margin and within four additional ROIs of the tumor center.
Diameters of the newly formed tumor microvessels were
measured perpendicularly to the vessel path (given in μm).
To study vascular permeability of the newly formed tumor
microvessels, petechial bleedings were documented in each
of the ROIs, and given as percentage of all the ROIs analyzed
[20, 21, 23].
2.7. Histology and Immunohistochemistry. At the end of the
experiment (day 14), the tumor and the adjacent host
tissue were harvested and immediately ﬁxed in formalin. For
light microscopy, formalin-ﬁxed biopsies were embedded in
paraﬃn. Sections of 5μm were cut and stained with hema-
toxylin and eosin (HE) according to standard procedures to
analyze tumor growth characteristics. Tumor cell invasion
of the muscular layer on the surface of the dorsal skinfold
chamberwasquantiﬁedovertheentiretumorbasisandgiven
as percentage of the length of the tumor basis.
To study tumor cell proliferation and apoptotic cell
death, proliferating cell nuclear antigen (PCNA) and cleaved
caspase-3 were stained using indirect immunoperoxidase
techniques. Therefore, deparaﬃnized sections were incu-
bated with 3% H2O2 and 2% goat normal serum to
block endogenous peroxidases and unspeciﬁc binding sites.
A monoclonal mouse anti-pan PCNA antibody (PC10,
DakoCytomation, Hamburg, Germany) and a polyclonal
rabbit anti-mouse cleaved caspase-3 antibody (Asp175, Cell
Signaling Technology, Frankfurt, Germany) were used as
primary antibodies. Goat anti-mouse and goat anti-rabbit
POD-conjugatedantibodieswereusedassecondaryantibod-
ies for streptavidin-biotin-complex peroxidase staining. 3,3 
diaminobenzidine (DakoCytomation) served as chromogen.
Sections were counterstained with Hemalaun according to
Mayer and examined by light microscopy.
ToassesstheexpressionofCD31asamarkerforendothe-
lial cells, zinc ﬁxative ﬁxed paraﬃn sections of tumor tissue
were used. After incubation with 3% H2O2 and 2% goat nor-
mal serum to block endogenous peroxidases and unspeciﬁc
binding sites, deparaﬃnized sections were incubated with a
rat anti-mouse CD31 antibody (MEC 13.3, BD Biosciences).
A polyclonal goat anti-rat IgG antibody (BD Biosciences)
was used as secondary antibody. Colorimetric detection was
performed using 3,3  diaminobenzidine (DakoCytomation)
substrates. Sections were counterstained with Hemalaun
according to Mayer and examined by light microscopy.
2.8. Flow Cytometric Analysis of CT26.WT-GFP Cells. FAC-
Scan (Becton Dickinson, Mountain View, CA, USA) analysis
was performed to assess the expression of c-Kit on the
CT26.WT-GFP cells in triplicate. Cells were ﬁxed with 2%
formalin, washed twice with PBS, resuspended in FACS
buﬀer and incubated with an FITC-conjugated rat anti-
mouse IgG2b c-Kit antibody (1:50; 553354, BD Biosciences)
or an FITC-conjugated isotype-matched control antibody
(553988, BD Biosciences). Cells were washed again and then
maintained in 2% paraformaldehyde in PBS. Tumor cells
were selectively analyzed for their ﬂuorescence properties
usingtheCellQuestdatahandlingprogram(BDBiosciences)
withassessmentof5000eventspersample.Theﬂowcytome-
ter was calibrated with ﬂuorescent standard microbeads
(CaliBRITE Beads, BD Biosciences).
2.9. Western Blot Analysis. To study protein expression
patterns,additionalWesternblotanalyseswereperformedon
tumor specimen gained from the dorsal skinfold chamber.
Therefore, 12 additional animals received CT26.WT-GFP
tumor cell implantation in the dorsal skinfold chamber
and were assigned to the three groups as described above.
Eight animals were pretreated with the anti-c-Kit antibody
(ACK45, BD Biosciences). Four of these pretreated animals
received additional treatment with the neutralizing anti-
SDF-1 antibody (MAB310, R and D Systems) starting at the
day of tumor cell implantation. Four animals received the
same amount of the corresponding isotype-matched control
antibody (A95-1, BD Biosciences).
For whole protein extracts and Western blot analysis of
the expression of vascular endothelial growth factor (VEGF),
the chemokine receptor CXCR4 and eNOS, CT26.WT-
GFP-tumors were completely removed from the skinfold4 Journal of Oncology
at day 5. The tumor tissue samples were homogenized
separately in lysis buﬀer and a protease inhibitor cock-
tail (Sigma, Taufkirchen, Germany), incubated on ice and
centrifuged at 16.000×g. The supernatant was saved as
whole protein extract fraction. Protein concentrations were
determined using the Lowry assay with bovine serum
albumin as standard. Ten microgram protein per lane
were separated discontinuously on sodium dodecyl sulfate
polyacrylamide gels (10% SDS-PAGE) and transferred to a
polyvinyldiﬂuoride membrane (0.2μm, BioRad, M¨ unchen,
Germany). After blockade of nonspeciﬁc binding sites,
membranes were incubated with an anti-VEGF antibody
(A-20, Santa Cruz, Heidelberg, Germany), an anti-CXCR4
antibody(ab2074,Abcam,Heidelberg,Germany),orananti-
eNOS antibody (BD Transduction Lab., Heidelberg, Ger-
many) followed by the corresponding secondary peroxidase-
conjugated antibodies (GE Healthcare, Freiburg, Germany
and Santa Cruz). Protein expression was visualized by
means of luminol enhanced chemiluminescence (ECL, GE
Healthcare) and exposure of the membranes to a blue-
light-sensitive autoradiography ﬁlm (Hyperﬁlm ECL, GE
Healthcare). Signals were densitometrically assessed (Bio-
Rad,Gel-Dokumentationssystem)andnormalizedtoβ-actin
signals (mouse monoclonal anti-β-actin, Sigma) to correct
for unequal loading.
2.10. Statistical Analysis. A l lv a l u e sa r ee x p r e s s e da sm e a n s
± SEM. After proving the assumption of normality and
homogeneity of variance across groups, diﬀerences between
groups were calculated by a one-way analysis of variance
(ANOVA) followed by the appropriate post hoc comparison,
including correction of the alpha error according to Bonfer-
roni probabilities to compensate for multiple comparisons.
Overall statistical signiﬁcance was set at P<0.05. Statistical
analysis was performed with the use of the software package
SigmaStat (SPSS Inc, Chicago, Ill).
3. Results
3.1. Tumor Growth. All animals had an uneventful post-
operative recovery and tolerated well the dorsal skinfold
chamber implantation and the repetitive intravital micro-
scopic analyses. The general conditions of the mice were not
aﬀected and no changes in feeding or sleeping habits were
observed. The take rate of the CT26.WT-GFP cells within
the dorsal skinfold chamber was 100%, and progressive
tumor growth was observed in all groups throughout the
entire observation period (Figures 1(a)–1(c)). Quantitative
analysis of the increase of the tumor area revealed a
signiﬁcantly enhanced engraftment of tumor cells and a
signiﬁcant stimulation of tumor growth after pretreatment
with the anti-c-Kit antibody compared to controls (P<
0.05). Interestingly, additional blockage of SDF-1 completely
bluntedthisenhancementoftumorgrowthleadingtosimilar
tumor sizes as measured in controls (P<0.05; Figure 1(d)).
3.2. Angiogenesis and Neovascularization. In control animals,
newly developed microvessels could be detected in ∼50%
of the ROIs by day 5 after tumor cell implantation. At
day 8, angiogenesis was seen in almost 100% of the ROIs.
Pretreatment with the anti-c-Kit antibody did not inﬂuence
the onset of the angiogenic switch compared to controls.
Of interest, blockade of SDF-1 after pretreatment with anti-
c-Kit signiﬁcantly delayed the angiogenic switch, with only
∼50% of the ROIs showing newly formed microvessels by
day 8 and ∼70% by day 11 (P<0.05). In this group,
angiogenesis was observed in all ROIs only at the end of the
observation period (Figure 2).
The diﬀerential eﬀects of c-Kit blockade with or without
additionalSDF-1blockadewerealsoreﬂectedbyquantitative
analysis of the microvascular densities of the newly formed
tumor vessels. As characteristic for tumor vessels, the vas-
cular network of the tumors consisted of irregularly shaped
and chaotically arranged microvessels (Figures 3(a)–3(c)).
Whereas no diﬀerences of microvascular density within
the tumor vasculature could be observed between controls
and anti-c-Kit pretreated animals, additional treatment
with the anti-SDF-1 antibody signiﬁcantly decreased the
microvascular density within the tumor center compared
to the other groups from day 8 until the end of the
observationperiod(Figure 3(d)).Quantitativeanalysisofthe
functional microvascular density within the tumor margin
showed similar results (data not shown). The functional
microvascular density within the tumor margin and the
tumor center was not signiﬁcantly diﬀerent within the
individual treatment groups.
In contrast to the highly vascularized CT26.WT-
GFP tumors within the intravital ﬂuorescence microscopy,
immunohistological staining for CD31 as a marker for
endothelial cells displayed positive staining of only a few cells
within tumor microvessels without signiﬁcant diﬀerences
between the three groups (data not shown).
As neovascularization is usually associated with vasodila-
tion due to the action of VEGF, microvessel diameters within
the tumor were analyzed. However, no overall diﬀerences
between the diameters of the microvessels within the tumor
margin and the tumor center could be observed (Table 1).
During the 14 days observation period, diameters slightly
increased in all groups until day 11, particularly in the
control and anti-c-Kit-pretreated groups. Of interest, at day
14,microvesseldiameterswithintumorsofmicetreatedwith
anti-c-Kit and anti-SDF-1 were markedly smaller compared
to the other two groups (Table 1).
Petechial bleedings within the areas of angiogenesis
of growing tumors are a characteristic indicator of the
VEGF action on vascular permeability. To study this VEGF-
induced increase of vascular permeability, we analyzed the
petechialbleedingswithintheROIsbyintravitalﬂuorescence
microscopy. Microbleedings were observed in all tumors. At
day 5, signs of petechial bleedings were observed in ∼6%
of the tumor area of control tumors, whereas petechial
bleedings occurred in up to 30% of the tumor area in
animals pretreated with anti-c-Kit at that time. In all groups,
petechialbleedingsweremostpronounced8daysaftertumor
cell implantation (control: 15–20%, anti-c-Kit: ∼30%, anti-
c-Kit/anti-SDF-1: 35–40%). Comparing the three groups,
no statistical signiﬁcance could be found due to the highJournal of Oncology 5
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Figure 1: Time course of tumor growth of CT26.WT-GFP tumors in the dorsal skinfold chamber. Stereomicroscopy photographs of
representative 14 days old tumors after either treatment with an isotype-matched control antibody (a), pretreatment with anti-c-Kit (b)
alone,orpretreatmentwithanti-c-Kitfollowedbyanti-SDF-1treatment(c).Quantitativeanalysisofthetumorarea(d)displayedprogressive
tumor growth in all groups. After anti-c-Kit pretreatment (grey triangles), tumor growth was signiﬁcantly accelerated compared to controls
(white circles). Of interest, additional neutralization of SDF-1 (black squares) completely blunted this anti-c-Kit-associated enhancement of
tumor growth. Mean ± SEM; ∗P<0.05 versus control; #P<0.05 versus anti-c-Kit. Original magniﬁcation (a)–(c) ×4.
Table 1: Microvessel diameters within the tumor margin and the tumor center of control animals, animals pretreated with anti-c-Kit and
animals pretreated with anti-c-Kit followed by anti-SDF-1 treatment. All values are given in μm. Diameters slightly increased during the
observation period. No signiﬁcant diﬀerences could be observed between the tumor margin and center. Fourteen days after tumor cell
implantation,microvasculardiameterswithinthetumorcenterweresigniﬁcantlysmallerinanti-c-Kit/anti-SDF-1treatedanimalscompared
to controls and to anti-c-Kit treated animals.
Time Control Anti-c-Kit Anti-c-Kit/anti-SDF-1
Tumor margin
d5 12.42 ±0.53 11.88 ±0.77 13.02 ±0.52
d8 13.97 ± 0.48 14.60 ±0.93 15.02 ±0.57
d11 14.73 ±1.36 15.39 ±1.00 14.84 ±1.06
d14 15.81 ±1.20 15.24 ±0.91 13.94 ±0.75
Tumor centre
d5 13.91 ±0.67 12.85 ±0.83 13.22 ±1.00
d8 14.44 ±0.52 13.93 ±0.75 14.21 ±0.47
d11 15.35 ±1.40 15.26 ±0.98 15.66 ±1.83
d14 16.86 ±1.10 16.84 ±1.35 12.82 ±0.67
∗#
Data are given as mean ± SEM; ∗P<0.05 versus control; #P<0.05 versus anti-c-Kit.6 Journal of Oncology
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Figure 2: Semiquantitative analysis of the onset of angiogenesis
within the CT 26.WT-GFP tumors. Animals were pretreated
with anti-c-Kit (grey triangles) alone or anti-c-Kit and anti-
SDF-1 neutralizing antibodies (black squares). Animals treated
with isotype-matched control antibodies served as controls (white
circles). In controls and anti-c-Kit pretreated animals, ∼50% of the
ROIs showed newly developed microvessels 5 days after tumor cell
implantation. By day 8, almost 100% of the ROIs were vascularized.
Treatment with anti-c-Kit and anti-SDF-1 resulted in a signiﬁcant
delayofangiogenesiswithonly ∼50and ∼70%oftheROIsshowing
newly developed microvessels by days 8 and 11. Within these
tumors, angiogenesis could be observed in all ROIs only at day 14.
Mean ± SEM; ∗P<0.05 versus control; #P<0.05 versus anti-c-Kit.
standard deviation within the individual groups (data not
shown).
3.3. Tumor Cell Migration. As SDF-1 has been demonstrated
to exert chemotactic eﬀects on CT26.WT-GFP tumor cells,
we additionally focused on migrating tumor cells next to
the tumor margin. The migrating tumor cells were easily
detectable due to their GFP labeling (Table 2). Starting at
day 5 after tumor cell implantation, tumor cell migration
was detectable in all tumors until the end of the observation
period with slightly increasing distances from the tumor
margin. The number of migrating tumor cells ranged
between 20 and 25 per representative ﬁeld during the
whole observation period. Treatment with anti-c-Kit alone
or additional blockade of SDF-1 did not impair tumor cell
migration compared to controls (Table 2).
3.4. Tumor Cell Morphology, Proliferation, and Apoptotic
Cell Death. Histologicalexaminationsonhematoxylin-eosin
stained sections revealed solid tumor growth within the
dorsal skinfold chamber. Signs of malignant tumor growth
such as invasion of the adjacent host tissue by the tumor
cells were detectable in each group (Figure 4). Quantitative
analysis of tumor cell invasion showed a signiﬁcant increase
of tumor cell inﬁltration through the muscular layer of
the dorsal skinfold chamber in tumors of animals which
were pretreated with anti-c-Kit compared to controls (P<
0.05). Of interest, tumors of animals additionally treated
with anti-SDF-1 showed a signiﬁcant reduction of muscular
inﬁltration compared to anti-c-Kit pretreated tumors (P<
0.05), resulting in invasive growth characteristics which were
comparable to controls (Figure 4(c)).
PCNA as an indicator of cell proliferation displayed
positive staining in 46.9 ± 3.1% of the tumor cells in control
animals (Figure 5). After pretreatment with anti-c-Kit, the
number of PCNA-positive tumor cells was signiﬁcantly
higher compared to controls (P<0.05, Figures 5(a) and
5(c)). In contrast, additional blockade of SDF-1 resulted in
a signiﬁcantly lower number of PCNA-positive tumor cells
compared to controls and to anti-c-Kit pretreated animals
(P<0.05, Figures 5(b) and 5(c)).
To study apoptotic cell death, immunohistochemical
staining of cleaved caspase-3 products within the tumors was
performed.Ofinterest,14daysaftertumorcellimplantation,
only a minor fraction of the total number of 351.3 ± 5.2
tumor cells within the high power ﬁelds (HPF) showed
positive staining for caspase-3. Whereas 0.73 ± 0.13 tumor
cells/HPF were positive for caspase-3 in controls, pretreat-
ment with anti-c-Kit reduced apoptotic cell death within the
tumors (0.26 ± 0.06 tumor cells/HPF). In tumors of animals
additionally treated with anti-SDF-1 antibodies, this eﬀect
was even more pronounced (0.15 ± 0.03 tumor cells/HPF,
P<0.05).
3.5. C-Kit Expression and Western Blot Analysis. FACScan
analysis demonstrated that 8.2 ± 0.8% of the CT26-GFP
cells transfected with the enhanced GFP expression vector
pEGFP-N1 was c-Kit receptor positive.
At day 5 after tumor cell implantation, the tumors
of animals pretreated with anti-c-Kit antibodies showed
a signiﬁcantly higher expression of VEGF and CXCR4
compared to controls (P<0.05; Figures 6(a) and 6(b)).
Additional SDF-1 blockade did not further increase VEGF
and CXCR4 expression. Furthermore, eNOS expression
within the tumors was decreased by anti-c-Kit pretreatment
withandwithoutadditionalanti-SDF-1treatmentcompared
to controls (data not shown).
4. Discussion
The major ﬁnding of the present study is that bone
marrow suppression by anti-c-Kit treatment signiﬁcantly
enhances tumor cell engraftment of colorectal tumors due
to an increase of tumor cell proliferation and invasion.
Additional anti-SDF-1 treatment neutralizes this increased
tumor outgrowth by inhibition of tumor cell proliferation
and tumor neovascularization. These ﬁndings suggest that
the enhanced tumor growth under the conditions of bone
marrow suppression induced by anti-c-Kit treatment is
related to the SDF-1/CXCR4 pathway.
Bone-marrow-derived hematopoetic cells (HCs) con-
tribute to physiological and pathological vessel forma-
tion. During tumor growth, the release of cytokines and
chemokines mediates the recruitment of EPCs and HCs
contributing to the early initiation and stabilization of
newly formed blood vessels, so-called vasculogenesis [24–
26]. However, their precise role has not been fully elucidatedJournal of Oncology 7
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Figure 3: Time course of the functional capillary density within CT-26.WT-GFP tumors in dorsal skinfold chambers analyzed by intravital
ﬂuorescence microscopy. Representative ﬂuorescence microscopic images show the network of chaotically arranged microvessels within
the tumor center of control animals (a), animals pretreated with anti-c-Kit (b), and animals additionally treated with anti-SDF-1 (c) at
day 11 after tumor cell implantation. Quantitative analysis of the functional capillary density (d) revealed a signiﬁcant inhibition of tumor
neovascularizationwithinthetumorcenteraftercombinedanti-c-Kitandanti-SDF-1treatment(blacksquares)comparedtocontrols(white
circles). Anti-c-Kit pretreatment alone (grey triangles) did not signiﬁcantly inﬂuence the extent of neovascularization. Mean ± SEM; ∗P<
0.05 versus control; #P<0.05 versus anti-c-Kit. Original magniﬁcation (a)–(c) ×40.
Table 2: Tumor cell migration in dorsal skinfold chambers of control animals, animals pretreated with anti-c-Kit, and animals pretreated
with anti-c-Kit followed by anti-SDF-1 treatment during a 14-day observation period. Migrated tumor cells next to the tumor margin
were observed from day 5 until the end of the observation time. Comparing all three groups, no signiﬁcant diﬀerences could be observed
concerning the total number of migrated cells as well as their distance [μm] from the tumor margin. Of interest, at the later time points,
tumor cells were found at greater distances from the tumor margin.
Time Control Anti-c-Kit Anti-c-Kit/anti-SDF-1
Number
d5 22.08 ±1.33 23.00 ±1.33 19.91 ±1.14
d8 22.67 ±1.33 23.14 ±1.18 20.67 ±1.07
d11 22.42 ±1.53 23.48 ±1.05 20.80 ±1.34
d14 20.84 ±1.71 23.96 ±1.32 21.17 ±1.30
Distance
d5 276.24 ±16.08 291.82 ±15.95 309.45 ±50.93
d8 337.94 ±9.38 351.11 ±23.57 323.38 ±20.45
d11 383.85 ±15.80 423.32 ±25.65 360.83 ±18.58
d14 421.50 ±22.40 438.49 ±32.01 458.51 ±59.01
Data are given as mean ± SEM.8 Journal of Oncology
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Figure 4: Hematoxylin-eosin staining of CT26.WT-GFP tumors shows solid tumor growth 14 days after tumor cell implantation within the
dorsal skinfold chamber. Sections display tumor inﬁltration through the underlying muscular layer (marked by arrows) after pretreatment
with anti-c-Kit (a) and lack of muscular inﬁltration after pretreatment with anti-c-Kit and additional neutralization of SDF-1 (b).
Quantitative analysis of tumor cell invasion of the muscular layer is given as percentage of the length of the tumor. Tumors of animals
pretreated with anti-c-Kit showed a signiﬁcantly pronounced inﬁltration of the muscular layer compared to controls. Of interest, blockade
of SDF-1 after anti-c-Kit pretreatment abrogated this anti-c-Kit-associated increase of tumor cell inﬁltration. Mean ± SEM; ∗P<0.05 versus
control; #P<0.05 versus anti-c-Kit. Original magniﬁcation (a, b) ×88.
yet. HCs and EPCs express stem cell markers such as c-Kit.
Whereas many studies indicate that bone-marrow-derived
EPCs incorporate into tumor neovessels [25, 27], HCs may
promote vasculogenesis via paracrine release of angiogenic
factors enhancing the recruitment and incorporation of
EPCs into neovessels [28].
In the early phases of tumor growth, 50–90% of the
neovessels within the tumor mass are derived from the bone
marrow dependent on the tumor type [25]. However, recent
reports have already doubted the impact of vasculogenesis
from bone-marrow-derived cells for tumor neovasculariza-
tion and claim an exclusive role for sprouting angiogenesis
in tumor blood vessel development [15, 16]. In a model of
syngeneic bone marrow transplantation, Patil et al. demon-
strated that GPF-expressing c-Kit+ bone-marrow-derived
progenitor cells are recruited to subcutaneously implanted
Lewis lung carcinoma but do not directly contribute to
microvascular structure. They, therefore, concluded that
even if circulating HCs and EPCs home to sites of tumor
growth, they do not contribute to tumor angiogenesis [29].
In a model of subcutaneously implanted prostate carcinoma,
Okamoto et al. observed an accumulation of HCs around
newly formed blood vessels, but did not ﬁnd these cells to be
part of the tumor microvessels themselves. Because of these
ﬁndings, the authors postulated a stabilizing and supportive
role of HCs for the developing vascular network [7].
In the present study, intravital ﬂuorescence microscopy
showed highly vascularized CT26.WT-GFP tumors 14 days
after tumor cell implantation. However, immunohistological
staining using the endothelial cell marker CD31 displayed
positive staining of only a few endothelial cells within these
tumors. This ﬁnding reﬂects the diverging structure between
normal microvessels and tumor neovessels which consist of
only cancer cells or a mosaic of cancer and endothelial cells
[2].
Previous experimental studies in mice have shown that a
depletionofthemyeloidanderythroidcelllineagesincluding
EPCs and HCs from the bone marrow could be performedJournal of Oncology 9
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Figure 5: PCNA immunohistochemistry in CT26.WT-GFP tumors at day 14 after tumor cell implantation. Animals were pretreated
with anti-c-Kit (cKit-Ab, (a)) alone or anti-c-Kit and anti-SDF-1 neutralizing antibodies (cKit/SDF1-Ab, (b)). Animals treated with an
isotype-matched control antibody served as controls (control). Quantitative analysis demonstrated that anti-c-Kit pretreatment signiﬁcantly
increasedtherateofproliferatingtumorcellscomparedtocontrols(c).Ofinterest,additionalneutralizationofSDF-1signiﬁcantlydecreased
the amount of proliferating tumor cells compared to controls and anti-c-Kit-treated animals. Mean ± SEM; ∗P<0.05 versus control;
#P<0.05 versus anti-c-Kit. Original magniﬁcation (a, b) ×175.
by daily injection of 1mg/kg ACK2, an antagonistic anti-
c-Kit antibody, which blocks the function of c-Kit without
cytotoxic side eﬀects on c-Kit+ cells [30, 31]. Of interest,
whereas no polymorphonuclear cells or erythroblasts were
present in the bone marrow of these ACK2-treated animals,
B lineage cells continued to grow to ﬁll the space from which
myeloid and erythroid progenitor cells were purged [30, 31].
Moreover, the reduction rate of the colony forming cells
within the bone marrow was dependent on the amount of
anti-c-Kitantibodies[30].Inthepresentstudy,we,therefore,
used the anti-c-Kit antibody in a dosage of 1mg/kg BW
for the induction of bone marrow suppression over a time
period of 4 days to avoid surgical complications and death
of the animals resulting from the immune incompetence by
bone marrow depletion.
As shown by Okamoto et al., bone marrow suppression
byanti-c-Kitpretreatmentoveratimeperiodof4daysbefore
subcutaneous implantation of colon tumor cells induced
leucopenia which was still detectable 10 days after the
last injection [7]. Although tumor growth and sprouting
of tumor vessels were slightly reduced in these studies of
Okamoto et al. during the ﬁrst 5–7 days, tumor growth
was rapidly reinitiated as the number of circulating HCs
in the peripheral blood increased again [7]. Therefore,
the authors concluded that HCs migrating into the tumor
mass promote the initiation of tumor neovascularization.
In our present study, although neoangiogenesis was not
inﬂuenced after administration of anti-c-Kit, tumor growth
was stimulated as a result of an increased tumor cell prolif-
eration and invasion. This observation might be the result
of immunological mechanisms that suppress tumor growth
in animals with an intact immune system. C-Kit blockade
for the induction of bone marrow suppression concurrently
stimulates B lymphopoiesis [30, 31]. As the number of B
cell precursors normally decreases in tumor bearing mice
[32,33],itmustbespeculatedthatinourexperimentofbone
marrow suppression, c-Kit blockade stimulates B cell genesis
and thus increases tumor cell engraftment. Furthermore, B
lymphopoiesis is associated with increased angiogenesis and
cellular proliferation [34–36]. In our study, neoangiogenesis10 Journal of Oncology
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Figure 6: Western blot analysis of VEGF (a) and CXCR4 (b) expression within CT 26.WT tumors ﬁve days after tumor cell implantation.
Animalswerepretreatedwithanti-c-Kit(cKit-Ab)aloneoradditionallytreatedwithaSDF-1neutralizingantibody(cKit/SDF1-Ab).Animals
treated with isotype-matched control antibodies served as controls (control). Quantitative analysis showed that VEGF expression was
signiﬁcantly higher after anti-c-Kit pretreatment than in control animals (a). Additional neutralization of SDF-1 had no further eﬀect on the
increased VEGF expression. CXCR4 was also signiﬁcantly higher expressed after anti-c-Kit pretreatment compared to controls and was not
further inﬂuenced by additional SDF-1 neutralization (b). Mean ± SEM; ∗P<0.05 versus control.
within the colorectal tumors of animals pretreated with
anti-c-Kit was comparable to controls despite the lack
of functional HCs which are necessary for angiogenesis
and vasculogenesis. Thus, we hypothesize that the lack of
HCs was compensated by local angiogenic factors or B
lymphopoiesis-associated angiogenesis, resulting in a tumor
neovascularization comparable to that observed in controls.
The SCF receptor c-Kit has been shown to be essential
for the development of blood cells, melanocytes, germ cells,
interstitial cells of Cajal in the gastrointestinal tract, and
mast cells [37]. Furthermore, the majority of tumor cells,
especially those of the neural axis, breast, lung, prostate,
and colon show an aberrant c-Kit expression [38]. Especially
gastrointestinal stromal tumors (GISTs) express c-Kit on the
cell-surface, and mutations of Kit in these tumors results in
an activation of Kit signaling, which leads to uncontrolled
cell proliferation and resistance to apoptosis [39, 40]. Today,
patients with GIST are treated with Imatinib, an inhibitor of
certain protein tyrosine kinases including KIT, depending on
the mitotic index of the GIST. Imatinib induces an arrest of
tumor cell proliferation and causes apoptotic cell death. In
established MCA26 tumors, Pan et al. showed that injection
of anti-c-Kit antibodies markedly reduces tumor-induced
immune tolerance exhibited by myeloid-derived suppressors
in mice [41]. Furthermore, their experiments demonstrate
that anti-c-Kit treatment can prevent tumor-speciﬁc T-cell
anergy and development of T regulatory cells (Treg). In
combination with an immune modulatory therapy of IL-12
plus 4-1BB activation, treatment with anti-c-Kit antibodies
signiﬁcantly improved the long-term survival of MCA26
tumor bearing mice [41]. In our study, only 8% of the
CT26.WT-GFP cells were c-Kit receptor positive. Therefore,
we do not expect a direct inhibitory eﬀect of anti-c-Kit
treatment on tumor cell proliferation.
Recruitment of HCs and EPC is predominantly mediated
by SDF-1 and its receptor CXCR4 [9, 10] because HCs and
EPCs migrate along a chemotactic gradient towards higher
concentrationsofSDF-1[12–14].Kaminskietal.haveshown
that almost 100% of bone marrow and peripheral blood c-
Kit+ cells are positive for CXCR4 [12]. In the present study,
wecoulddemonstratethatneutralizationofSDF-1afteranti-
c-Kit pretreatment signiﬁcantly reduces neovascularization
most probably by the inhibition of HC and EPC recruitment
within the tumors. Additionally, in combination with anti-c-
Kit pretreatment, SDF-1 neutralization is capable of decreas-
ing tumor cell proliferation and invasion. Taken together,
neutralization of SDF-1 counteracts the stimulating eﬀects
of bone marrow suppression by anti-c-Kit treatment on
tumor cell engraftment and inhibits compensatory local and
B lymphopoiesis-associated angiogenesis.
As described by Kaminski et al., the presence of SDF-
1 chemoattractant activity and inﬂammatory endothelial
activation by TNF-α is required for c-Kit+ cells to form
functionally relevant interactions with the endothelium in
postcapillary venules [12]. Blockade of ICAM-1 and CXCR4
abolishes adhesion of c-Kit+ cells to the vascular endothe-
lium despite application of SDF-1 and TNF-α.M o r e o v e r ,
in their cremaster muscle microcirculation model, stem cellJournal of Oncology 11
adhesion was signiﬁcantly reduced when eNOS was not
present or systemic NOS inhibited [12]. As SDF-1 and TNF-
α stimulation activates the endothelium by an increase of the
CXCR4 expression leading to relevant stem cell attraction
[12], our results indicate that the increase of CXCR4 and
VEGF expression within the tumors represents a compen-
satory pathway after anti-c-Kit pretreatment. Neutralization
of SDF-1 inhibits interactions of c-Kit positive cells with
tumor vessels and as a consequence, leads to inhibition of
tumor neovascularization.
In conclusion, bone marrow suppression by anti-c-Kit
pretreatment signiﬁcantly enhances tumor cell engraftment
of colorectal tumors. As anti-SDF-1 treatment counteracts
this increased tumor outgrowth by inhibition of neovascu-
larization,theSDF-1/CXCR4pathwayseemstobecrucialfor
tumor angiogenesis mediated by HCs and EPCs.
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